Journal: bioRxiv

Article Title: Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer

doi: 10.1101/2025.10.06.675352

Figure Lengend Snippet: ( A ) Carboplatin and Triplatin chemical structures. ( B and C ) Cytotoxicity of carboplatin and Triplatin on human OVTOKO and JHOC5 cancer cell lines; 1h treatment. ( D ) Flow cytometry of 200 nM and 50 nM rVAR2-V5 binding to ES2 wt cells, ES2 wt cells + chABC treatment, or Xylt1/Xylt2 KO cells. ( E and F ) Cytotoxicity of carboplatin and Triplatin in ES2 wt and Xylt1/Xylt2 KO cell lines; 1h treatment. ( G and H ). Platinum cellular accumulation in ES2 wt and Xylt1/Xylt2 KO cells treated with 10 µM carboplatin or Triplatin for 1, 2, 4, and 8h. Platinum content was measured by inductively coupled plasma mass spectroscopy (ICP-MS) and normalized by number of cells. ( I and J ). Platinum-DNA adducts in ES2 wt and Xylt1/Xylt2 KO cells treated with 10 µM carboplatin or Triplatin 4, and 8h. ( K and M ) ES2-luc wt and Xylt1/Xylt2 KO tumors were implanted on the left and right flanks mice. Tumors were harvested after 24h treatment with 40 mg/kg i.p Carboplatin or 0.3 mg/kg i.p. Triplatin. Tumors were digested in nitric acid and platinum measured by ICP-MS.

Article Snippet: Bound peptide was detected with mouse anti-V5 antibody (R960-25, ThermoFisher; 1:700 in casein buffer, 45 min, room temperature), followed by Leica post-primary rabbit anti-mouse antibody (8 min) and goat anti-rabbit HRP conjugate (8 min), with PBS washes between each step.

Techniques: Flow Cytometry, Binding Assay, Clinical Proteomics, Mass Spectrometry

Journal: bioRxiv

Article Title: Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer

doi: 10.1101/2025.10.06.675352

Figure Lengend Snippet: Representative images of rVAR2-V5 and H&E OC PDX staining and Qupath analysis. (C) Qupath segmentation of rVAR2-V5 (+), rVAR2-V5 (-), and necrotic tumor area in OC PDX models. (D) Sensitivity of OC PDX models to Triplatin and carboplatin. OC PDX models were treated i.p. with carboplatin (40 mg/kg) or Triplatin (0.3 mg/kg) on days 0, 4 and 8 (orange arrows). * * p<0.01, * * * * p<0.0001, 2-way ANOVA, Tukey

Article Snippet: Bound peptide was detected with mouse anti-V5 antibody (R960-25, ThermoFisher; 1:700 in casein buffer, 45 min, room temperature), followed by Leica post-primary rabbit anti-mouse antibody (8 min) and goat anti-rabbit HRP conjugate (8 min), with PBS washes between each step.

Techniques: Staining

Journal: bioRxiv

Article Title: Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer

doi: 10.1101/2025.10.06.675352

Figure Lengend Snippet: (A) UVA CHTN OC TMA; Representative samples of patient OC subtypes (clinical history unknown) and (B) normal tissues stained with rVAR2-V5 protein. (C) UVA CHTN OC TMA; Percentage of sample area staining positively for rVAR2-V5. Values are representative of the mean of 4 cores per patient sample. (D) UVA CHTN OC TMA; Percentage of TMA samples above the cut-off score. (E) UPenn CCC TMA samples; Percentage of sample area staining positively for rVAR2-V5.

Article Snippet: Bound peptide was detected with mouse anti-V5 antibody (R960-25, ThermoFisher; 1:700 in casein buffer, 45 min, room temperature), followed by Leica post-primary rabbit anti-mouse antibody (8 min) and goat anti-rabbit HRP conjugate (8 min), with PBS washes between each step.

Techniques: Staining